|
TW252044B
(US20050026921A1-20050203-C00021.png)
*
|
1992-08-10 |
1995-07-21 |
Boehringer Ingelheim Kg |
|
|
US5877179A
(en)
*
|
1992-09-29 |
1999-03-02 |
The United States Of America As Represented By The Department Of Health And Human Services |
Xanthines for identifying CFTR--binding compounds useful for activating chloride conductance in animal cells
|
|
WO1994025462A1
(en)
*
|
1993-05-03 |
1994-11-10 |
The United States Of America, Represented By The |
8-substituted 1,3,7-trialkyl-xanthine derivatives as a2-selective adenosine receptor antagonists
|
|
DE4316576A1
(de)
*
|
1993-05-18 |
1994-11-24 |
Boehringer Ingelheim Kg |
Verbessertes Verfahren zur Herstellung von 1,3-Dipropyl-8-(3-Oxocyclopentyl)-xanthin
|
|
US5646156A
(en)
*
|
1994-04-25 |
1997-07-08 |
Merck & Co., Inc. |
Inhibition of eosinophil activation through A3 adenosine receptor antagonism
|
|
US5591776A
(en)
|
1994-06-24 |
1997-01-07 |
Euro-Celtique, S.A. |
Pheynl or benzyl-substituted rolipram-based compounds for and method of inhibiting phosphodiesterase IV
|
|
GB9415529D0
(en)
|
1994-08-01 |
1994-09-21 |
Wellcome Found |
Phenyl xanthine derivatives
|
|
DE69531555T2
(de)
|
1994-12-13 |
2004-06-17 |
Euroceltique S.A. |
Dreifachsubstituierte thioxanthine
|
|
CA2206287C
(en)
*
|
1994-12-13 |
2001-03-20 |
Mark Chasin |
Aryl thioxanthines
|
|
US5864037A
(en)
|
1996-06-06 |
1999-01-26 |
Euro-Celtique, S.A. |
Methods for the synthesis of chemical compounds having PDE-IV inhibitory activity
|
|
GB9623859D0
(en)
*
|
1996-11-15 |
1997-01-08 |
Chiroscience Ltd |
Novel compounds
|
|
US5786360A
(en)
|
1996-11-19 |
1998-07-28 |
Link Technology Incorporated |
A1 adenosine receptor antagonists
|
|
GB9703044D0
(en)
|
1997-02-14 |
1997-04-02 |
Glaxo Group Ltd |
Phenyl xanthine esters and amides
|
|
US6248746B1
(en)
|
1998-01-07 |
2001-06-19 |
Euro-Celtique S.A. |
3-(arylalkyl) xanthines
|
|
WO1999031101A1
(en)
*
|
1997-12-17 |
1999-06-24 |
University Of South Florida |
Adenosine receptor antagonists with improved bioactivity
|
|
DE19816857A1
(de)
*
|
1998-04-16 |
1999-10-21 |
Boehringer Ingelheim Pharma |
Neue unsymmetrisch substituierte Xanthin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
|
WO2000002861A1
(en)
|
1998-07-10 |
2000-01-20 |
The United States Of America, Represented By Secretary, Department Of Health And Human Services |
A3 adenosine receptor antagonists
|
|
GB9817623D0
(en)
|
1998-08-13 |
1998-10-07 |
Glaxo Group Ltd |
Pharmaceutical compounds
|
|
AU784556B2
(en)
*
|
1999-11-12 |
2006-05-04 |
Biogen Idec Ma Inc. |
Polycycloalkylpurines as adenosine receptor antagonists
|
|
WO2001034604A2
(en)
|
1999-11-12 |
2001-05-17 |
Biogen, Inc. |
Adenosine receptor antagonists and methods of making and using the same
|
|
CA2395414A1
(en)
*
|
1999-12-24 |
2001-07-05 |
Kyowa Hakko Kogyo Co., Ltd |
Condensed purine derivative
|
|
AU2001230913B2
(en)
|
2000-01-14 |
2005-06-30 |
The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Methanocarba cycloalkyl nucleoside analogues
|
|
CN100408579C
(zh)
*
|
2001-02-24 |
2008-08-06 |
贝林格尔英格海姆法玛两合公司 |
黄嘌呤衍生物,其制法及其作为药物组合物的用途
|
|
UA80258C2
(en)
*
|
2001-09-06 |
2007-09-10 |
Biogen Inc |
Methods of treating pulmonary disease
|
|
AU2003231805A1
(en)
|
2002-06-17 |
2004-02-09 |
Glaxo Group Limited |
Purine derivatives as liver x receptor agonists
|
|
US7407955B2
(en)
|
2002-08-21 |
2008-08-05 |
Boehringer Ingelheim Pharma Gmbh & Co., Kg |
8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
|
|
US7569574B2
(en)
|
2002-08-22 |
2009-08-04 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Purine derivatives, the preparation thereof and their use as pharmaceutical compositions
|
|
US7495005B2
(en)
|
2002-08-22 |
2009-02-24 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Xanthine derivatives, their preparation and their use in pharmaceutical compositions
|
|
US7482337B2
(en)
*
|
2002-11-08 |
2009-01-27 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
|
|
DE10254304A1
(de)
|
2002-11-21 |
2004-06-03 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
|
|
CA2516250A1
(en)
*
|
2003-02-19 |
2004-09-02 |
Endacea, Inc. |
A1 adenosine receptor antagonists
|
|
BRPI0409699A
(pt)
|
2003-04-25 |
2006-04-18 |
Novacardia Inc |
métodos de indução do efeito diurético, de indução, manutenção ou restauração do efeito diurético de diurético não modificador de adenosina, de manutenção, restauração ou melhoria da função renal em paciente, de indução de diurese, de prevenção do inìcio de deficiência renal em paciente com sobrecarga de fluidos ou chf, de tratamento de paciente que sofre de chf e de melhoria dos resultados globais da saúde, composição farmacêutica e seus usos
|
|
EP1636229A4
(en)
*
|
2003-06-06 |
2008-07-30 |
Endacea Inc |
ADENOSINE A1 RECEPTOR ANTAGONISTS
|
|
JP2007506804A
(ja)
*
|
2003-06-09 |
2007-03-22 |
エンダセア， インコーポレイテッド |
Ａ１アデノシンレセプターアンタゴニスト
|
|
US7566707B2
(en)
|
2003-06-18 |
2009-07-28 |
Boehringer Ingelheim International Gmbh |
Imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions
|
|
DE10355304A1
(de)
*
|
2003-11-27 |
2005-06-23 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue 8-(Piperazin-1-yl)-und 8-([1,4]Diazepan-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
|
|
US7501426B2
(en)
|
2004-02-18 |
2009-03-10 |
Boehringer Ingelheim International Gmbh |
8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
|
|
DE102004009039A1
(de)
|
2004-02-23 |
2005-09-08 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
8-[3-Amino-piperidin-1-yl]-xanthine, deren Herstellung und Verwendung als Arzneimittel
|
|
US7393847B2
(en)
|
2004-03-13 |
2008-07-01 |
Boehringer Ingleheim International Gmbh |
Imidazopyridazinediones, their preparation and their use as pharmaceutical compositions
|
|
US7179809B2
(en)
*
|
2004-04-10 |
2007-02-20 |
Boehringer Ingelheim International Gmbh |
2-Amino-imidazo[4,5-d]pyridazin-4-ones, their preparation and their use as pharmaceutical compositions
|
|
US7439370B2
(en)
|
2004-05-10 |
2008-10-21 |
Boehringer Ingelheim International Gmbh |
Imidazole derivatives, their preparation and their use as intermediates for the preparation of pharmaceutical compositions and pesticides
|
|
DE102004030502A1
(de)
|
2004-06-24 |
2006-01-12 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue Imidazole und Triazole, deren Herstellung und Verwendung als Arzneimittel
|
|
DE102004043944A1
(de)
|
2004-09-11 |
2006-03-30 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue 8-(3-Amino-piperidin-1-yl)-7-(but-2-inyl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
|
|
DE102004044221A1
(de)
|
2004-09-14 |
2006-03-16 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue 3-Methyl-7-butinyl-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
|
|
DE102004054054A1
(de)
|
2004-11-05 |
2006-05-11 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
|
|
DE102005035891A1
(de)
|
2005-07-30 |
2007-02-08 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
|
|
EP1852108A1
(en)
*
|
2006-05-04 |
2007-11-07 |
Boehringer Ingelheim Pharma GmbH & Co.KG |
DPP IV inhibitor formulations
|
|
PE20080251A1
(es)
|
2006-05-04 |
2008-04-25 |
Boehringer Ingelheim Int |
Usos de inhibidores de dpp iv
|
|
EA015687B1
(ru)
|
2006-05-04 |
2011-10-31 |
Бёрингер Ингельхайм Интернациональ Гмбх |
Полиморфы
|
|
WO2008017670A1
(en)
*
|
2006-08-08 |
2008-02-14 |
Boehringer Ingelheim International Gmbh |
Pyrrolo [3, 2 -d] pyrimidines as dpp-iv inhibitors for the treatment of diabetes mellitus
|
|
EP3542801A1
(en)
*
|
2007-08-17 |
2019-09-25 |
Boehringer Ingelheim International GmbH |
Purin derivatives for use in the treatment of fap-related diseases
|
|
WO2009086077A2
(en)
|
2007-12-21 |
2009-07-09 |
Endacea, Inc. |
A1 adenosine receptor antagonists
|
|
US7928259B2
(en)
*
|
2008-02-12 |
2011-04-19 |
Frx Polymers, Inc. |
Diaryl alkylphosphonates and methods for preparing same
|
|
AR071175A1
(es)
|
2008-04-03 |
2010-06-02 |
Boehringer Ingelheim Int |
Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante
|
|
PE20100156A1
(es)
*
|
2008-06-03 |
2010-02-23 |
Boehringer Ingelheim Int |
Tratamiento de nafld
|
|
UY32030A
(es)
|
2008-08-06 |
2010-03-26 |
Boehringer Ingelheim Int |
"tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
|
|
KR20190016601A
(ko)
|
2008-08-06 |
2019-02-18 |
베링거 인겔하임 인터내셔날 게엠베하 |
메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
|
|
CN103816158A
(zh)
*
|
2008-08-15 |
2014-05-28 |
勃林格殷格翰国际有限公司 |
用于治疗fab-相关疾病的嘌呤衍生物
|
|
CA2736421A1
(en)
|
2008-09-10 |
2010-03-18 |
Boehringer Ingelheim International Gmbh |
Combination therapy for the treatment of diabetes and related conditions
|
|
JP5334511B2
(ja)
*
|
2008-09-22 |
2013-11-06 |
日本精化株式会社 |
化粧料
|
|
US20200155558A1
(en)
|
2018-11-20 |
2020-05-21 |
Boehringer Ingelheim International Gmbh |
Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
|
|
CN107011345A
(zh)
|
2008-12-23 |
2017-08-04 |
勃林格殷格翰国际有限公司 |
有机化合物的盐形式
|
|
AR074990A1
(es)
|
2009-01-07 |
2011-03-02 |
Boehringer Ingelheim Int |
Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
|
|
CN102361557A
(zh)
*
|
2009-03-26 |
2012-02-22 |
Mapi医药公司 |
制备阿格列汀的方法
|
|
EA034869B1
(ru)
|
2009-11-27 |
2020-03-31 |
Бёрингер Ингельхайм Интернациональ Гмбх |
Лечение генотипированных пациентов с диабетом ингибиторами дпп-4, такими как линаглиптин
|
|
EP2507241A1
(en)
|
2009-12-02 |
2012-10-10 |
The U.S.A. As Represented By The Secretary, Department Of Health And Human Services |
Methanocarba adenosine derivatives and dendrimer conjugates thereof
|
|
EP2566469B1
(en)
|
2010-05-05 |
2022-12-21 |
Boehringer Ingelheim International GmbH |
Combination therapy
|
|
CN102971005A
(zh)
|
2010-06-24 |
2013-03-13 |
贝林格尔.英格海姆国际有限公司 |
糖尿病治疗
|
|
US9034883B2
(en)
|
2010-11-15 |
2015-05-19 |
Boehringer Ingelheim International Gmbh |
Vasoprotective and cardioprotective antidiabetic therapy
|
|
EP2731947B1
(en)
|
2011-07-15 |
2019-01-16 |
Boehringer Ingelheim International GmbH |
Substituted dimeric quinazoline derivative, its preparation and its use in pharmaceutical compositions for the treatment of type i and ii diabetes
|
|
US9555001B2
(en)
|
2012-03-07 |
2017-01-31 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition and uses thereof
|
|
JP6224084B2
(ja)
|
2012-05-14 |
2017-11-01 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
糸球体上皮細胞関連障害及び／又はネフローゼ症候群の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
|
|
WO2013174767A1
(en)
|
2012-05-24 |
2013-11-28 |
Boehringer Ingelheim International Gmbh |
A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
|
|
JP6615109B2
(ja)
|
2014-02-28 |
2019-12-04 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Ｄｐｐ−４阻害薬の医学的使用
|
|
WO2017211979A1
(en)
|
2016-06-10 |
2017-12-14 |
Boehringer Ingelheim International Gmbh |
Combinations of linagliptin and metformin
|
|
RU2643336C1
(ru)
*
|
2016-10-03 |
2018-01-31 |
Общество с Ограниченной Ответственностью "Компания "ЭЛТА" |
СРЕДСТВО, ПРОЯВЛЯЮЩЕЕ АНТИТРОМБОТИЧЕСКИЙ ЭФФЕКТ ПОСРЕДСТВОМ БЛОКИРОВАНИЯ РЕЦЕПТОРОВ ТРОМБОЦИТОВ ГП IIb-IIIa (ВАРИАНТЫ)
|
|
CN109796453A
(zh)
*
|
2019-02-12 |
2019-05-24 |
南京纽邦生物科技有限公司 |
一种1,7-二甲基黄嘌呤的制备方法
|
|
US20240002416A1
(en)
|
2020-10-15 |
2024-01-04 |
Rheinische-Friedrich-Wilhelms-Universität Bonn |
MRGPRX4 Agonists and Antagonists
|
